WebbBiography. Mr. Michael Bonney serves as Chief Executive Officer, Board Member and Executive Chairman at Kaleido BioSciences. He served as Board Member at Celgene. He joins the Kaleido team from Cubist Pharmaceuticals, where he served as CEO and Director and led it to become the world's leading antibiotic company, which was acquired by … Webb4 aug. 2024 · The estimated Net Worth of Michael W Bonney is at least 2.95 百万$ dollars as of 13 June 2024. Mr. Bonney owns over 902 units of Alnylam Pharmaceuticals Inc stock worth over 2,448,321$ and over the last 11 years he sold ALNY stock worth over 0$. In addition, he makes 505,707$ as Independent Chairman of the Board at Alnylam …
Michael Bonney Profile: Contact Information & Network PitchBook
Bonney joined Boston-based company Third Rock Ventures as a partner in early 2015 and left in late 2016. His position encompassed guiding start up companies to financial viability and encourage marketplace completion in the field of bio medicine. He gave angel funds to a start up called X4 Pharmaceuticals in late 2014. Upon his retirement Bonney was appointed to numerous boards including NPS Pharmaceuticals… Webb28 okt. 2024 · "On behalf of Alnylam’s Board, we are deeply grateful to John’s remarkable and storied leadership of Alnylam for all these years. There’s no doubt that John is … othh p3dv5
Alnylam Names Dr. Yvonne Greenstreet New CEO
Webb5 jan. 2024 · Mr. Bonney will be stepping down from his interim role as Executive Chair where he was focused on integrating the ethics and compliance function at Alnylam, a role he assumed for just over a year during which the company appointed a new Chief Ethics and Compliance Officer. Webb28 okt. 2024 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around … Webb4 aug. 2024 · The estimated Net Worth of Michael W Bonney is at least $3.48 million dollars as of 13 June 2024. Mr. Bonney owns over 902 units of Alnylam … rock ola wandbox